CXS Therapeutics

CXS Therapeutics is developing the first neuroprotective treatment against Parkinson’s disease. The startup, in preclinical phase at Inserm Tours, aims to slow disease progression by directly targeting the mechanisms of neuronal degeneration.

Scientific context

Parkinson’s disease affects more than 200,000 people in France alone. Existing treatments alleviate symptoms but do not halt progression. CXS Therapeutics proposes a neuroprotective approach — a goal the scientific community has pursued for two decades.

What Dotation.org brings

Dotation.org supports CXS Therapeutics in its early-stage phase: funding for the first preclinical tests, networking with other deeptech actors, operational guidance.

This page is a placeholder. The actual content will be enriched with the CXS team.